Fluconazole levels in serum and cerebrospinal fluid according to daily dosage in patients with cryptococcosis and other fungal infections

AUTOR(ES)

Schiave, Letícia Aparecida, Nascimento, Erika, Vilar, Fernando Crivelenti, de Haes, Tissiana Marques, Takayanagui, Osvaldo Massaiti, Gaitani, Cristiane Masetto de, Martinez, Roberto

FONTE

Braz J Infect Dis

DATA DE PUBLICAÇÃO

2018-01

RESUMO

ABSTRACT Fluconazole is extensively used for the treatment of candidiasis and cryptococcosis. Among other factors, successful treatment is related to appropriate fluconazole levels in blood and cerebrospinal fluid. In the present study, fluconazole levels were determined in 15 patients, 14 of whom had AIDS and 13 had neurocryptococcosis. The only selection criterion was treatment with fluconazole, which was performed with a generic or similar form of the drug. Fluconazole level was determined by high performance liquid chromatography and the susceptibility profile of Cryptococcus spp. isolated from the patients was assessed by broth microdilution. Blood and cerebrospinal fluid fluconazole levels were found to be related to the fluconazole daily dose, and exceeded the minimum inhibitory concentration of this antifungal for the Cryptococcus spp. isolates. A good correlation was observed between serum and cerebrospinal fluid drug concentration. In conclusion, treatment with non-original fluconazole under usual medical practice conditions results in appropriate blood and cerebrospinal fluid levels of the drug for inhibiting Cryptococcus spp. susceptible to this antifungal drug. The relatively common failures of neurocryptococcosis treatment appear not to be due to insufficient fluconazole levels in the cerebrospinal fluid, especially with the use of daily doses of 400–800 mg.

Documentos Relacionados

• Pharmacokinetics of fluconazole in cerebrospinal fluid and serum in human coccidioidal meningitis.
• Pharmacokinetics of fluconazole in cerebrospinal fluid and serum of rabbits: validation of an animal model used to measure drug concentrations in cerebrospinal fluid.
• Anticysticercous antibodies in serum and cerebrospinal fluid in patients with cerebral cysticercosis.
• Serum and cerebrospinal fluid S100B concentrations in patients with neurocysticercosis
• Serum and cerebrospinal fluid S100B concentrations in patients with neurocysticercosis